<DOC>
	<DOCNO>NCT00720564</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-ray kill tumor cell . Drugs use chemotherapy , arsenic trioxide temozolomide , work different way stop growth tumor cell , either kill cell stop dividing . Arsenic trioxide temozolomide may also make tumor cell sensitive radiation therapy . Giving radiation therapy together combination chemotherapy may kill tumor cell . PURPOSE : This phase I trial study side effect best dose arsenic trioxide give together temozolomide radiation therapy treat patient newly diagnose high-grade glioma .</brief_summary>
	<brief_title>Radiation Therapy , Arsenic Trioxide , Temozolomide Treating Patients With Newly Diagnosed High-Grade Glioma</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose arsenic trioxide administer sequentially temozolomide radiotherapy patient newly diagnose glioblastoma multiforme . - Determine dose-limiting toxicity regimen patient . OUTLINE : This dose-escalation study arsenic trioxide . Patients undergo radiotherapy ( may intensity-modulated ) day 1-5 . Patients also receive arsenic trioxide IV 1-2 hour day 1-5 , oral temozolomide day 1-7 . Treatment radiotherapy , arsenic trioxide , temozolomide repeat every week 6 week absence disease progression unacceptable toxicity . Patients may receive oral temozolomide day 1-5 . Treatment repeat every 4 week 12 course absence disease progression . After completion study therapy , patient follow periodically .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose grade III IV glioma include follow : Glioblastoma Anaplastic astrocytoma Gliosarcoma Anaplastic oligodendroglioma Anaplastic oligoastrocytoma Measurable nonmeasurable disease No 5 week since prior brain surgery Recovered surgery , post operative infection , complication Preoperatively postoperatively diagnostic contrastenhanced MRI CT scan brain perform prior radiation therapy Patients diagnose stereotactic biopsy require postoperative scan PATIENT CHARACTERISTICS : Karnofsky performance status ≥ 60 % Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Serum creatinine ≤ 1.5 time upper limit normal ( ULN ) Total bilirubin ≤ 2.0 mg/dL AST ≤ 4.0 time ULN No prolong QT interval &gt; 460 millisecond baseline electrocardiogram presence normal serum potassium magnesium No uncontrolled electrolyte imbalance ( i.e. , sodium &lt; 132 mmol/L , potassium &lt; 3.5 mEq/dL , magnesium &lt; 1.7 mg/dL ) No history torsades de pointes type ventricular arrhythmia Negative pregnancy test Not pregnant nursing Fertile patient must use effective contraception No medical psychiatric illness , investigator 's opinion , could potentially preclude completion study therapy No HIV positivity No active connective tissue disorder ( e.g. , lupus scleroderma ) , investigator 's opinion , may put patient high risk radiation toxicity PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior brain radiotherapy chemotherapy brain tumor Concurrent corticosteroid control cerebral edema allow provide dose stable decrease past 5 day No concurrent plan receive drug know prolong QT interval No prior radiation head neck ( except T1 glottic cancer ) result overlap radiation field</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult mixed glioma</keyword>
</DOC>